Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingAvalon Healthcare Oral Cancer Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedAvalon Healthcare SolutionsPolicy AHS - G2113

    Oral Cancer Screening and Testing

    Customize your policy alerts

    Sign up for avalon_healthcare_solutions Policy AHS - G2113 alerts

    Get alerted when Policy AHS - G2113 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage for screening, detection, diagnosis, and HPV tumor-status testing related to oral and oropharyngeal cancer, subject to the member’s benefit plan and applicable government coverage policies.

    Policy Summary
    PayerAvalon Healthcare Solutions
    PolicyOral Cancer Screening and Testing
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJune 1, 2026
    Last ReviewMar 5, 2026
    Next Review DateN/A
    Key ActionUse high-risk HPV E6/E7 mRNA expression testing or p16 immunohistochemistry to establish HPV tumor status for an eligible cancer diagnosis.
    SourceLink
    POLICY UPDATE CHANGES

    Coverage was expanded to include high-risk HPV testing to establish HPV tumor status in individuals with metastatic squamous cell carcinoma of unknown primary origin in a cervical lymph node.

    Detection of HPV from an oropharyngeal swab, such as the OmniPathology Oropharyngeal HPV PCR Test, was added as a test that does not meet coverage criteria.

    CPT code 87626 was added and the description for CPT code 87624 was revised.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2Covered HPV tumor-status indications
    5Non-covered oral cancer testing categories
    2Covered testing methods
    2Codes added or revised
    14High-risk HPV types in referenced swab test
    2026Latest committee approval

    Coverage Criteria

    HPV Tumor-Status Testing

    Testing meets coverage criteria when ALL of the following are satisfied:

    ALL of the following

    • Eligible clinical indication

      • The individual has oropharyngeal squamous cell carcinoma.
      • The individual has metastatic squamous cell carcinoma of unknown primary origin in a cervical lymph node.
    • Specified testing method

      • Testing for high-risk HPV using mRNA expression testing for HPV E6/E7.
      • Testing for high-risk HPV using immunohistochemistry for p16 expression.

    Non-Covered Oral Cancer Screening and Diagnostic Testing

    Testing to screen, detect, or diagnose oral cancer does not meet coverage criteria when it involves ANY of the following categories:

    ANY of the following testing categories

    • Salivary biomarker testing, including peptides/proteins, nucleic acids, or metabolites.
    • Genotyping of HPV, such as OraRisk® HPV.
    • Gene expression profiling.
    • Panels that incorporate genetic risk factors with nongenetic biomarkers, such as mRNA CancerDetect™.
    • Detection of HPV from an oropharyngeal swab, such as the OmniPathology Oropharyngeal HPV PCR Test.

    Establishing HPV Tumor Status

    Coverage is established for the clinical use of high-risk HPV testing to establish tumor status when ALL of the following apply:

    ALL of the following

    • Cancer diagnosis or presentation

      • Oropharyngeal squamous cell carcinoma is present.
      • Metastatic squamous cell carcinoma of unknown primary origin is present in a cervical lymph node.
    • Testing method

      • High-risk HPV mRNA expression testing for HPV E6/E7 is performed.
      • Immunohistochemistry for p16 expression is performed.

    Oral Cancer Screening and Detection Tests That Do Not Meet Coverage Criteria

    Oral cancer screening and detection testing does not meet coverage criteria when the testing is used for screening, detection, or diagnosis rather than to establish HPV tumor status in an eligible cancer presentation.

    Exclusion logic

    • The testing is intended to screen for, detect, or diagnose oral cancer.
    • Affected testing category

      • Salivary biomarker testing, including peptides/proteins, nucleic acids, or metabolites.
      • HPV genotyping, including OraRisk® HPV.
      • Gene expression profiling.
      • Panels combining genetic risk factors with nongenetic biomarkers, including mRNA CancerDetect™.

    Coverage is limited to high-risk HPV testing used to establish tumor status in individuals with oropharyngeal squamous cell carcinoma or metastatic squamous cell carcinoma of unknown primary origin in a cervical lymph node, when testing uses mRNA expression for HPV E6/E7 or immunohistochemistry for p16 expression. Salivary biomarker testing, HPV genotyping such as OraRisk® HPV, gene expression profiling, and panels combining genetic risk factors with nongenetic biomarkers such as mRNA CancerDetect™ do not meet coverage criteria for screening, detection, or diagnosis of oral cancer. Detection of HPV from an oropharyngeal swab, such as the OmniPathology Oropharyngeal HPV PCR Test, also does not meet coverage criteria.

    The OmniPathology oropharyngeal swab test is designed to screen asymptomatic individuals for high-risk HPV in the oropharynx and does not depend on clinical signs, symptoms, or a confirmed tumor. Routine oropharyngeal swab screening in asymptomatic individuals is not recommended in the latest cancer guidelines, including the CAP 2025 guideline, which does not recommend routine screening for oropharyngeal squamous cell carcinoma or HPV-associated head and neck cancers in asymptomatic individuals. Endorsed testing is based on a confirmed or suspected tumor identified by imaging or biopsy, diagnostic workup of nodal metastases, histological evidence, or specific staging, prognostic, or therapeutic decisions.

    Testing modalities that do not meet coverage criteria lack sufficient published scientific literature confirming that they are required and beneficial for diagnosing or treating an individual's illness. This exclusion includes salivary biomarkers, HPV genotyping, gene expression profiling, biomarker panels incorporating genetic and nongenetic factors, and HPV detection from an oropharyngeal swab when used to screen for, detect, or diagnose oral cancer. The coverage criteria for establishing HPV tumor status are separate and apply only to the specified eligible cancer presentations and testing methods.

    Applicable Codes

    Applicable CPT/HCPCS procedure codesCPT
    81599Unlisted multianalyte assay with algorithmic analysis.
    82397Chemiluminescent assay.
    88341Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure).
    88342Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure.
    Applicable proprietary molecular test codeCPT
    0429UHuman papillomavirus (HPV), oropharyngeal swab, 14 high-risk types (ie, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68).
    Codes revised or added in revision historyCPT
    87626CPT code added in the 03/05/2026 off-cycle coding modification; the full description is not provided in this document window.
    87624CPT code whose description was revised in the 03/05/2026 off-cycle coding modification; the full revised description is not provided in this document window.

    Provider and Billing Guidance

    Denial Risk

    Excluded Oral Cancer Screening and Diagnostic Tests

    Do not submit oral cancer screening, detection, or diagnostic testing for coverage when it falls within the excluded categories below. These services do not meet coverage criteria and are at high risk for denial; verify the member’s benefit plan and applicable government coverage before billing.

    • Coverage criteria apply subject to the member’s benefit coverage and plan contract; the plan contract controls if there is a conflict.
    • Do not interpret this exclusion as applying to covered high-risk HPV testing used to establish HPV tumor status in qualifying oropharyngeal squamous cell carcinoma or metastatic squamous cell carcinoma of unknown primary origin in a cervical lymph node.
    Denial Risk

    Insufficient Supporting Evidence

    Testing does not meet coverage criteria when available published scientific literature does not establish that the test is required and beneficial for diagnosing or treating the individual’s illness. Document the clinical indication and supporting evidence, but expect denial when the evidence requirement is not met.

    Clinical Background

    Oral cancer arises in the oral cavity, extending from the vermilion border of the lips to the junction of the hard and soft palates or to the posterior one-third of the tongue. Squamous cell carcinoma is the most common type of oral cancer. Oropharyngeal squamous cell carcinoma may be associated with high-risk HPV; p16 immunohistochemistry is used as a surrogate marker of HPV tumor status.

    Definitions and Testing Methods

    HPV
    TermHPV
    DefinitionHuman papillomavirus
    Policy contextHigh-risk HPV tumor status is evaluated in oropharyngeal cancer and related squamous cell carcinoma indications.
    IHC
    TermIHC
    DefinitionImmunohistochemistry
    Policy usep16 expression detected by IHC is used as a surrogate biomarker for HPV status.

    Covered Clinical Indications

    Establishing HPV Tumor Status in Oropharyngeal or Metastatic Squamous Cell Carcinoma

    Covered when both the diagnosis and the testing method requirements are met.

    Covered indication

    • Covered testing method

      • High-risk HPV E6/E7 mRNA expression testing is used.
      • p16 immunohistochemistry is used.

    Establishing HPV Tumor Status in Oropharyngeal Squamous Cell Carcinoma

    Covered when performed to establish HPV tumor status using one of the specified methods.

    Covered indication

    • Covered testing method

    Non-Covered Services

    The following services are not covered when used to screen, detect, or diagnose oral or oropharyngeal cancer: HPV genotyping, including OraRisk HPV; gene expression profiling; salivary biomarker testing involving peptides, proteins, nucleic acids, or metabolites; panels combining genetic risk factors with nongenetic biomarkers, including mRNA CancerDetect; and HPV detection from an oropharyngeal swab, including the OmniPathology Oropharyngeal HPV PCR Test. Routine oropharyngeal HPV swab screening is also not recommended for asymptomatic individuals by the cited cancer guidelines.

    Policy Summary
    PayerAvalon Healthcare Solutions
    PolicyOral Cancer Screening and Testing
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJune 1, 2026
    Last ReviewMar 5, 2026
    Next Review DateN/A
    Key ActionUse high-risk HPV E6/E7 mRNA expression testing or p16 immunohistochemistry to establish HPV tumor status for an eligible cancer diagnosis.
    SourceLink
    On This Page
    Coverage CriteriaApplicable CodesProvider and Billing GuidanceClinical BackgroundDefinitions and Testing MethodsCovered Clinical IndicationsNon-Covered Services
  1. HPV detection from an oropharyngeal swab, including the OmniPathology Oropharyngeal HPV PCR Test.
  2. Coverage determinations remain subject to the individual’s benefit coverage at the time of the request.
  3. Applicable Medicare LCDs/NCDs, Medicaid requirements, or other government policies may control when they conflict with this policy.
  4. Denial Risk

    Excluded Oral Cancer Testing Categories

    The following testing does not meet coverage criteria when used to screen, detect, or diagnose oral cancer. Code and bill these services with awareness that they are excluded under this policy and may be denied.

    • Salivary biomarker testing, including peptides/proteins, nucleic acids, or metabolites.
    • HPV genotyping, such as OraRisk® HPV.
    • Gene expression profiling.
    • Panels incorporating genetic risk factors with nongenetic biomarkers, such as mRNA CancerDetect™.
    • Detection of HPV from an oropharyngeal swab, such as the OmniPathology Oropharyngeal HPV PCR Test.
    HR-HPV
    TermHR-HPV
    DefinitionHigh-risk human papillomavirus infection
    Clinical contextHigh-risk HPV testing is recommended for newly diagnosed oropharyngeal squamous cell carcinoma and metastatic squamous cell carcinoma of unknown primary in a cervical lymph node.
    mRNA
    TermmRNA
    DefinitionMessenger ribonucleic acid
    Policy useHPV E6/E7 mRNA detection is used as a specific method and gold-standard reference for determining HPV tumor status.
    LDT
    TermLDT
    DefinitionLaboratory-developed test
    PerformanceAn LDT is developed, validated, and performed in-house by a laboratory.
    CLIA '88
    TermCLIA '88
    DefinitionClinical Laboratory Improvement Amendments of 1988
    Policy roleCLIA '88 provides the regulatory framework under which laboratory-developed tests are classified as high-complexity tests.
    HR-HPV testing
    PurposeHigh-risk HPV testing is used to evaluate HPV tumor status.
    Oropharyngeal tissue specimensFor oropharyngeal tissue specimens, testing uses p16 immunohistochemistry as a surrogate marker.
    HPV-specific methodsHPV-specific testing may be performed when p16 staining is equivocal, discordant with morphology, or required by the clinical setting.
    p16 immunohistochemistry
    DefinitionImmunohistochemical detection of p16 expression.
    Biomarker rolep16 immunohistochemistry is a surrogate biomarker for HPV status in oropharyngeal cancer.
    Testing relationshipp16 expression has very good agreement with HPV status determined by HPV E6/E7 mRNA expression.
    HPV E6/E7 mRNA expression testing
    DefinitionDetection of HPV E6/E7 messenger RNA.
    Clinical useThe test is used as a specific method for determining HPV tumor status.
    Reference standardE6/E7 mRNA detection is described as the gold standard for evaluating the performance of plasma cell-free HPV DNA assays.
    Laboratory-developed test
    DefinitionA laboratory-developed test is validated and performed by a laboratory.
    CLIA classificationLDTs are regulated by CMS as high-complexity tests under CLIA '88.
    FDA statusLDTs are not FDA-approved or FDA-cleared; FDA clearance or approval is not currently required for clinical use.
    Operational requirementLaboratories must validate and perform these tests in-house.
    • High-risk HPV E6/E7 mRNA expression testing is used.
    • p16 immunohistochemistry is used.

    Establishing HPV Tumor Status in Metastatic Squamous Cell Carcinoma of Unknown Primary Origin

    Covered when performed to establish HPV tumor status using one of the specified methods.

    Covered indication

    • Covered testing method

      • High-risk HPV E6/E7 mRNA expression testing is used.
      • p16 immunohistochemistry is used.